Literature DB >> 8832525

Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy.

R J Levy1, J A Sparano, G Khan.   

Abstract

Acute rhabdomyolysis has rarely been reported after cytotoxic chemotherapy, including cytarabine and 5-azacytidine. We observed a case of acute rhabdomyolysis and renal failure after treatment with mitoxantrone and cyclophosphamide. No other cause of muscle injury could be identified, although biochemical analysis of a muscle biopsy specimen revealed a deficiency of muscle phosphorylase activity. Retreatment with doxorubicin and paclitaxel was not associated with recurrent rhabdomyolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8832525     DOI: 10.1007/bf02990567

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  11 in total

1.  Chemotherapy-related acute rhabdomyolysis.

Authors:  C Papakonstantinou; K Papanastasiou; M Kotsopoulou; M Mouratidou; D Sotiropoulos; M C Kyrtsoni; A Pouli; M Stamatelou; A Maniatis
Journal:  J Natl Cancer Inst       Date:  1992-04-01       Impact factor: 13.506

2.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

Authors:  J L Speyer; M D Green; A Zeleniuch-Jacquotte; J C Wernz; M Rey; J Sanger; E Kramer; V Ferrans; H Hochster; M Meyers
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

3.  Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.

Authors:  L J Ayash; J E Wright; O Tretyakov; R Gonin; A Elias; C Wheeler; J P Eder; A Rosowsky; K Antman; E Frei
Journal:  J Clin Oncol       Date:  1992-06       Impact factor: 44.544

4.  Rhabdomyolysis associated with high-dose cytarabine.

Authors:  D Margolis; E Ross; K B Miller
Journal:  Cancer Treat Rep       Date:  1987-12

5.  The spectrum of rhabdomyolysis.

Authors:  P A Gabow; W D Kaehny; S P Kelleher
Journal:  Medicine (Baltimore)       Date:  1982-05       Impact factor: 1.889

6.  Rhabdomyolysis as a complication of 5-azacytidine.

Authors:  H P Koeffler; C M Haskell
Journal:  Cancer Treat Rep       Date:  1978-04

7.  Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer.

Authors:  L M Lewkow; J L Hooker; A Movahed
Journal:  Int J Cardiol       Date:  1992-03       Impact factor: 4.164

8.  Metabolic causes of myoglobinuria.

Authors:  P Tonin; P Lewis; S Servidei; S DiMauro
Journal:  Ann Neurol       Date:  1990-02       Impact factor: 10.422

9.  Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.

Authors:  M Estorch; I Carrió; D Martínez-Duncker; L Berná; G Torres; C Alonso; B Ojeda
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

10.  Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans.

Authors:  R P Rago; J M Miles; R L Sufit; D R Spriggs; G Wilding
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860

View more
  2 in total

1.  Severe acute rhabdomyolysis induced by multi-agent chemotherapy for alveolar rhabdomyosarcoma in a 15-year-old female: a case report.

Authors:  Hiroshi Matsuzaki; Yuhki Koga; Aiko Suminoe; Utako Oba; Tomohito Takimoto; Toshiro Hara
Journal:  Case Rep Oncol       Date:  2013-07-31

2.  Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report.

Authors:  Alexandra Sokolova; Onyee Chan; Waqas Ullah; Auon Abbas Hamdani; Faiz Anwer
Journal:  J Med Case Rep       Date:  2017-04-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.